Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme

BACKGROUND AND AIMS: Patients with inflammatory bowel disease have increased risk of atherosclerotic cardiovascular [CV] disease [ASCVD]. Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis [UC]. We report major adverse CV events [MACE] in the UC OCTAVE programme,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiber, Stefan, Rubin, David T, Ng, Siew C, Peyrin-Biroulet, Laurent, Danese, Silvio, Modesto, Irene, Guo, Xiang, Su, Chinyu, Kwok, Kenneth K, Jo, Hyejin, Chen, Yan, Yndestad, Arne, Reinisch, Walter, Dubinsky, Marla C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673809/
https://www.ncbi.nlm.nih.gov/pubmed/37402275
http://dx.doi.org/10.1093/ecco-jcc/jjad104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673809/
https://www.ncbi.nlm.nih.gov/pubmed/37402275
http://dx.doi.org/10.1093/ecco-jcc/jjad104

Ejemplares similares